Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orthofix Medical (OFIX) Other financing activities (2016 - 2025)

Historic Other financing activities for Orthofix Medical (OFIX) over the last 15 years, with Q2 2025 value amounting to $19000.0.

  • Orthofix Medical's Other financing activities fell 9775.15% to $19000.0 in Q2 2025 from the same period last year, while for Sep 2025 it was $1.5 million, marking a year-over-year decrease of 6388.3%. This contributed to the annual value of $3.6 million for FY2024, which is 5400.93% up from last year.
  • Latest data reveals that Orthofix Medical reported Other financing activities of $19000.0 as of Q2 2025, which was down 9775.15% from $512000.0 recorded in Q1 2025.
  • Orthofix Medical's Other financing activities' 5-year high stood at $1.9 million during Q4 2021, with a 5-year trough of -$385000.0 in Q1 2021.
  • Over the past 5 years, Orthofix Medical's median Other financing activities value was $192500.0 (recorded in 2022), while the average stood at $454875.0.
  • Per our database at Business Quant, Orthofix Medical's Other financing activities skyrocketed by 192173.91% in 2023 and then tumbled by 9775.15% in 2025.
  • Over the past 5 years, Orthofix Medical's Other financing activities (Quarter) stood at $1.9 million in 2021, then crashed by 91.47% to $160000.0 in 2022, then surged by 936.25% to $1.7 million in 2023, then tumbled by 38.9% to $1.0 million in 2024, then crashed by 98.12% to $19000.0 in 2025.
  • Its last three reported values are $19000.0 in Q2 2025, $512000.0 for Q1 2025, and $1.0 million during Q4 2024.